There is evidence to support the fact that patients with COVID-19 are at risk of coagulopathy and other thromboembolic complications which increase the risk of mortality.15 Administering low molecular weight heparin or rivaroxaban, a factor Xa inhibitor, was to reduce this risk among 14 (58.3%) of our hospitalized patients. Here, F10 is linked to blood coagulation disease.